A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future

References

• BurrowsB, BloomJW, TraverGA, ClineMG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987;317(21):1309–1314. doi:10.1056/NEJM1987111931721033683459
   PubMed Web of Science ®Google Scholar
• OrieNG, Slutter HJ deVRIE, TammelingGJ. Chronic nonspecific respiratory diseases. Ned Tijdschr Geneeskd. 1961;28(105):2136–2139.
   Google Scholar
• LangeP, CelliB, AgustiA, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373(2):111–122. doi:10.1056/NEJMoa141153226154786
   PubMed Web of Science ®Google Scholar
• BarnesPJ. Asthma-COPD Overlap. Chest. 2016;149(1):7–8. doi:10.1016/j.chest.2015.08.01726757281
   PubMed Web of Science ®Google Scholar
• MiravitllesM, Alvarez-GutierrezFJ, CalleM, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J. 2017;49(5):1700068. doi:10.1183/13993003.00068-201728461301
   PubMed Web of Science ®Google Scholar
• Pérez-de-LlanoL, CosioBG. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respir Res. 2017;18(1):183. doi:10.1186/s12931-017-0667-x29096609
   PubMed Web of Science ®Google Scholar
• AgustiA, BelE, ThomasM, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-201526828055
   PubMed Web of Science ®Google Scholar
• PavordID, BeasleyR, AgustiA, et al. After asthma: redefining airways diseases. Lancet. 2017;S0140-6736(17)30879–6.
   Web of Science ®Google Scholar
• McDonaldVM, FingletonJ, AgustiA, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J. 2019;53(5):1802058. doi:10.1183/13993003.02058-201830846468
   PubMed Web of Science ®Google Scholar
• SuissaS, ErnstP, BenayounS, BaltzanM, CaiB. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–336. doi:10.1056/NEJM20000803343050410922423
   PubMed Web of Science ®Google Scholar
• GuptaRP, MukherjeeM, SheikhA, StrachanDP. Persistent variations in national asthma mortality, hospital admissions and prevalence by socioeconomic status and region in England. Thorax. 2018;73(8):706–712. doi:10.1136/thoraxjnl-2017-21071430006496
   PubMed Web of Science ®Google Scholar
• MroczekB, KurpasD, UrbanM, SitkoZ, GrodzkiT. The influence of asthma exacerbations on health-related quality of life. Adv Exp Med Biol. 2015;873:65–77.26285613
   PubMed Web of Science ®Google Scholar
• McCoyL, RedelingsM, SorvilloF, SimonP. A multiple cause-of-death analysis of asthma mortality in the United States, 1990–2001. J Asthma. 2005;42(9):757–763. doi:10.1080/0277090050030818916316870
   PubMed Web of Science ®Google Scholar
• O’ByrnePM, PedersenS, LammCJ, TanWC, BusseWW. START investigators group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19–24. doi:10.1164/rccm.200807-1126OC18990678
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• Martínez-GarcíaMA, AthanazioR, GramblickaG, CorsoM, Cavalcanti LundgreF. Prognostic value of frequent exacerbations in bronchiectasis: the relationship with disease severity. Arch Bronconeumol. 2019;55(2):81–87. doi:10.1016/j.arbres.2018.07.00230119935
   PubMed Web of Science ®Google Scholar
• BloechligerM, ReinauD, SpoendlinJ, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75. doi:10.1186/s12931-018-0742-y29699563
   PubMed Web of Science ®Google Scholar
• KoFW, HuiDS, LeungTF, et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012;17(2):370–378. doi:10.1111/j.1440-1843.2011.02105.x22107482
   PubMed Web of Science ®Google Scholar
• CasanovaC, MarínJM, Martínez-GonzálezC, et al. Differential effect of modified medical research council dyspnea, COPD assessment test and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest. 2015;148(1):159–168. doi:10.1378/chest.14-244925612228
   PubMed Web of Science ®Google Scholar
• EngelkesM, JanssensHM, de JongsteJC, SturkenboomMC, VerhammeKM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407. doi:10.1183/09031936.0007561425323234
   PubMed Web of Science ®Google Scholar
• TranN, CoffmanJM, SuminoK, CabanaMD. Patient reminder systems and asthma medication adherence: a systematic review. J Asthma. 2014;51(5):536–543. doi:10.3109/02770903.2014.88857224506699
   PubMed Web of Science ®Google Scholar
• NormansellR, KewKM, StovoldE. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;18(4):CD012226.
   Google Scholar
• VestboJ, AndersonJA, CalverleyPM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943. doi:10.1136/thx.2009.11366219703830
   PubMed Web of Science ®Google Scholar
• BryantJ, McDonaldVM, BoyesA, Sanson-FisherR, PaulC, MelvilleJ. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013;14(1):109. doi:10.1186/1465-9921-14-10924138097
   PubMed Web of Science ®Google Scholar
• PolosaR, RussoC, CaponnettoP, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. Respir Res. 2011;12(1):16. doi:10.1186/1465-9921-12-1621261960
   PubMed Web of Science ®Google Scholar
• ChaudhuriR, LivingstonE, McMahaonAD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174(2):127–133. doi:10.1164/rccm.200510-1589OC16645173
   PubMed Web of Science ®Google Scholar
• GodtfredesenNS, LamTH, HanselTT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32(4):844–853. doi:10.1183/09031936.0016000718827152
   PubMed Web of Science ®Google Scholar
• Pérez De LlanoLA, GonzálezFC, AñónOC, PereaMP, CarunchoMV, VillarAB. Relationship between comorbidity and asthma control. Arch Bronconeumol. 2010;46(10):508–513. doi:10.1016/j.arbres.2010.05.00820638762
   PubMed Web of Science ®Google Scholar
• BachertC, ZhangL, GevaertP. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440. doi:10.1016/j.jaci.2015.10.01026654192
   PubMed Web of Science ®Google Scholar
• Serrano-ParienteJ, PlazaV, SorianoJB, et al. CPASMA trial group. Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea. Allergy. 2017;72(5):802–812. doi:10.1111/all.1307027732758
   PubMed Web of Science ®Google Scholar
• DivoM, CoteC, de TorresJP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
   PubMed Web of Science ®Google Scholar
• Figueira GonçalvesJM, García BelloMÁ, Martín MartínezMD, García-TalaveraI, GolpeR. Can the COPD-comorbidome be applied to all outpatients with chronic obstructive pulmonary disease? A single-center analysis. Arch Bronconeumol. 2019;S0300-2896(19)30212–1. doi:10.1016/j.arbres.2019.03.016
   Web of Science ®Google Scholar
• Mc DonnellMJ, AlibertiS, GoeminnePC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016;4(12):969–979. doi:10.1016/S2213-2600(16)30320-427864036
   PubMed Web of Science ®Google Scholar
• MarínJM, SorianoJB, CarrizoSJ, BoldovaA, CelliBR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010;182(3):325–331. doi:10.1164/rccm.200912-1869OC20378728
   PubMed Web of Science ®Google Scholar
• BensonVS, MüllerovaH, VestboJ, WedzichaJA, PatelA, HurstJR. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147–1154. doi:10.1016/j.rmed.2015.06.00926166017
   PubMed Web of Science ®Google Scholar
• KitchBT, PaltielAD, KuntzKM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004;126(6):1875–1882. doi:10.1378/chest.126.6.187515596687
   PubMed Web of Science ®Google Scholar
• SchatzM, SorknessCA, LiJT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549–556. doi:10.1016/j.jaci.2006.01.01116522452
   PubMed Web of Science ®Google Scholar
• KerstjensHA, EngelM, DahlR, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa120860622938706
   PubMed Web of Science ®Google Scholar
• CasaleTB, BatemanED, VandewalkerM, et al. Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935. doi:10.1016/j.jaip.2017.08.03729174062
   PubMed Web of Science ®Google Scholar
• CelliBR, CoteCG, MarínJM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• SchleichFN, ChevremontA, PaulusV, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108. doi:10.1183/09031936.0020181324525441
   PubMed Web of Science ®Google Scholar
• CowanDC, TaylorDR, PetersonLE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–883. doi:10.1016/j.jaci.2014.10.02625488689
   PubMed Web of Science ®Google Scholar
• PetskyHL, LiA, ChangAB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017;24(8):CD005603.
   Google Scholar
• FarneHA, WilsonA, PowellC, BaxL, MilanSJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;21(9):CD010834.
   Google Scholar
• SiddiquiSH, GuasconiA, VestboJ, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE26051430
   PubMed Web of Science ®Google Scholar
• PavordID, LettisS, LocantoreN, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;71(2):118–125. doi:10.1136/thoraxjnl-2015-20702126585525
   PubMed Web of Science ®Google Scholar
• PascoeS, LocantoreN, DransfieldMT, BarnesNC, PavordID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X25878028
   PubMed Web of Science ®Google Scholar
• HindsDR, DiSantostefanoRL, LeHV, PascoeS. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016;6(6):e010099. doi:10.1136/bmjopen-2015-010099
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• de la Rosa CarrilloD, López-CamposJL, Alcázar NavarreteB, et al. Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;S0300-2896(20)30145–9. doi:10.1016/j.arbres.2020.04.023
   Web of Science ®Google Scholar
• López-CamposJL, MiravitllesM, De la Rosa CarrilloD, CantónR, Soler-CataluñaJJ, Martínez-GarcíaMA. Current challenges in chronic bronchial infection in patients with chronic obstructive pulmonary disease. J Clin Med. 2020;9(6):E1639. doi:10.3390/jcm906163932481769
   PubMed Web of Science ®Google Scholar
• GibsonPG, YangIA, UphamJW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi:10.1016/S0140-6736(17)31281-328687413
   PubMed Web of Science ®Google Scholar
• SeemungalTAR, WilkinsonTMA, HurstJR, PereraWR, SapsfordRJ, WedzichaJA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–1147. doi:10.1164/rccm.200801-145OC18723437
   PubMed Web of Science ®Google Scholar
• UzunS, DjaminRS, KluytmansJA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomized, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. doi:10.1016/S2213-2600(14)70019-024746000
   PubMed Web of Science ®Google Scholar
• AlbertRK, ConnettJ, BaileyWC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa110462321864166
   PubMed Web of Science ®Google Scholar
• SethiS, JonesPW, TheronMS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11(1):10. doi:10.1186/1465-9921-11-1020109213
   PubMed Web of Science ®Google Scholar
• Martinez-GarciaMA, MaizL, OlveiraC, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):88–98. doi:10.1016/j.arbr.2017.07.01429128129
   PubMed Web of Science ®Google Scholar
• KimV, HanMK, VanceGB, et al. The chronic bronchitis phenotype of COPD: an analysis of the COPDGene study. Chest. 2011;140(3):626–633. doi:10.1378/chest.10-294821474571
   PubMed Web of Science ®Google Scholar
• WedzichaJA, CalverleyPM, RabeKF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;6(11):81–90. doi:10.2147/COPD.S89849
   Web of Science ®Google Scholar
• Martínez-RiveraC, CrespoA, Pinedo-SierraC, et al. Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations. Respir Med. 2018;135:22–28. doi:10.1016/j.rmed.2017.12.01329414449
   PubMed Web of Science ®Google Scholar
• BatemanED, GoehringUM, RichardF, WatzH. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138(1):142–149. doi:10.1016/j.jaci.2015.11.03526915674
   PubMed Web of Science ®Google Scholar
• Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;681–685.6110912
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med. 1980;93(3):391–398. doi:10.7326/0003-4819-93-3-3916776858
   PubMed Web of Science ®Google Scholar
• FoucherP, BaudoinN, MeratiM, et al. Relative survival analysis of 252 patients with COPD receiving long-term oxygen therapy. Chest. 1998;6(6):1580–1587. doi:10.1378/chest.113.6.1580
   Web of Science ®Google Scholar
• KöhnleinT, WindischW, KöhlerD, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014;2(9):698–705. doi:10.1016/S2213-2600(14)70153-525066329
   PubMed Web of Science ®Google Scholar
• MurphyPB, RehalS, ÀrbaneG, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177–2186. doi:10.1001/jama.2017.445128528348
   PubMed Web of Science ®Google Scholar
• StruikFM, SprootenRT, KerstjensHA, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilator support for acute respiratory failure: a randomized, controlled, parallel-group study. Thorax. 2014;69(9):826–834. doi:10.1136/thoraxjnl-2014-20512624781217
   PubMed Web of Science ®Google Scholar
• PetskyHL, KewKM, TurnerC, ChangAB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;1(9):CD011440.
   Google Scholar
• Alcázar-NavarreteB, Castellano MiñánF, Santiago DíazP, Ruiz RodríguezO, Romero PalaciosPJ. Alveolar and bronchial nitric oxide in chronic obstructive pulmonary disease and asthma-COPD overlap. Arch Bronconeumol. 2018;54(8):414–419. doi:10.1016/j.arbres.2018.02.00629627118
   PubMed Web of Science ®Google Scholar
• HohlfeldJM, Vogel-ClaussenJ, BillerH, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi:10.1016/S2213-2600(18)30054-729477448
   PubMed Web of Science ®Google Scholar
• SontJK, WillemsLN, BelEH, van KriekenJH, VandenbrouckeJP, SterkPJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group. Am J Respir Crit Care Med. 1999;159(4):1043–1051. doi:10.1164/ajrccm.159.4.980605210194144
   PubMed Web of Science ®Google Scholar
• HospersJJ, PostmaDS, RijckenB, WeissST, SchoutenJP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356(9238):1313–1317. doi:10.1016/S0140-6736(00)02815-411073020
   PubMed Web of Science ®Google Scholar
• BafadhelM, PetersonS, De BlasMA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• LazarusSC, KrishnanJA, KingTS, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2019;380(21):2009–2019. doi:10.1056/NEJMoa181491731112384
   PubMed Web of Science ®Google Scholar
• KupczykM, HaqueS, MiddelveldRJ, DahlénB, DahlénSE. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med. 2013;107(10):1521–1530. doi:10.1016/j.rmed.2013.07.01423993706
   PubMed Web of Science ®Google Scholar
• Ten BrinkeA, ZwindermanAH, SterkPJ, RabeKF, BelEH. “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med. 2004;170(6):601–605. doi:10.1164/rccm.200404-440OC15215154
   PubMed Web of Science ®Google Scholar
• WuW, BangS, BleeckerER, et al. Multiview cluster analysis identifies variable corticosteroid response phenotypes in severe asthma. Am J Respir Crit Care Med. 2019;199(11):1358–1367. doi:10.1164/rccm.201808-1543OC30682261
   PubMed Web of Science ®Google Scholar
• WoodruffPG, Barmak ModrekDF, ChoyGJ, et al. T-helper type 2–driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:10.1164/rccm.200903-0392OC19483109
   PubMed Web of Science ®Google Scholar
• BerthonBS, GibsonPG, WoodLG. A sputum gene expression signature predicts oral corticosteroid response in asthma. Eur Respir J. 2017;49(6):1700180. doi:10.1183/13993003.00180-201728663317
   PubMed Web of Science ®Google Scholar
• PolverinoE, GoeminnePC, McDonnellMJ, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-201728889110
   PubMed Web of Science ®Google Scholar